Showing 601-610 of 6661 results for "".
Take 5: Significant Features of Senate Healthcare Legislation
https://practicaldermatology.com/columns/take-5/take-5significant-features-of-senate-healthcare-legislation/22051/The now defunct cosmetic surgery tax isn't the only element of healthcare reform to impact dermatologists, their practices/businesses, or their patients.Scientifically Speaking: Expert Filler Tips and Cases
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-expert-filler-tips-and-cases/20005/Optimal outcomes with aesthetic injectables depend on choosing the right filler and applying the proper technique. Michael Somenek, MD; Kay Durairaj, MD; Shino Bay Aguilera, DO; and Corey Hartman, MD share cases and discuss the secrets to natural-looking, impressive improvements in the lips, chin,SCALE 2024: Listen as Dr. Joel Cohen and Dr. Suneel Chilukuri on Microwave Therapy
https://practicaldermatology.com/error/404/Suneel Chilukuri, MD, discusses the various applications of microwave therapy, including non-melanoma skin cancer, with Joel Cohen, MD, at Music City SCALE.An Inside Look at How Incyte is Addressing Unmet Needs of Patients with Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/an-inside-look-at-how-incyte-is-addressing-unmet-needs-of-patients-with-atopic-dermatitis/20156/Ahmad Naim, Vice President of US Medical Affairs at Incyte, discusses the challenges around atopic dermatitis (AD) management and how Incyte is utilizing its expertise in immunology to address unmet needs for patients.DermWireTV: Dupixent for Kids; Epsolay Launch; Scleroderma Awareness; Chicago Derms Celebrate Diversity
https://practicaldermatology.com/topics/practice-management/dermwiretv-dupixent-for-kids-epsolay-launch-scleroderma-awareness-chicago-derms-celebrate-diversity/20100/Epsolay (benzoyl peroxide 5%) Cream from Galderma is now available for the topical treatment of rosacea. It was developed by Sol-Gel. Dupixent from Sanofi and Regeneron is now the only biologic medicine FDA approved for use from infancy through adulthood for the management of atopic dermatitis. JuneAnatomy Lesson: Targeting the Underlying Cause of Wrinkles with Injections
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/anatomy-lesson-targeting-the-underlying-cause-of-wrinkles-with-injections/19778/Patients need to understand that addressing the underlying causes of wrinkles and folds such as changes in bony structures with injectables will provide a more natural result than simply chasing wrinkles and folds, says Jeanette M. Black, MD.DermwireTV — Bayer Buys Merck’s OTC Lines, Allergan Rejects Valeant Bid
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-bayer-buys-merck-rsquo-s-otc-lines-allergan-rejects-valeant-bid/19134/Bayer Purchases Merck's OTC Products and Allergan Rebuffs Valeant. This week DermWireTV explores Bayer's growth in the OTC space, including sunscreens, and reports new data on skin cancer mortality. Also in this edition: Neal Bhatia, MD reviews the Noah Worcester Society Annual Meeting.Part 2, 1726 nm lasers: All about the AviClear and Accure devices from clinical trial to today, including pulsing protocols and pain control methods
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24340/Chapter 2 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about the AviClear and Accure devices from clinical trial to today, including pulsing protocols and pain control methods.Experts React to Latest Benzene Analysis
https://practicaldermatology.com/series/dermwire-tv/experts-react-to-latest-benzene-analysis/29810/In this week's DermwireTV, Practical Dermatology Editorial Board members provide their thoughts on the recent analysis examining benzene concentrations in BPO products; Johnson & Johnson seeks new indications for IL-23 inhibitor Tremfya; and the founder and CEO of Terns discusses plans to improvDermwireTV: FDA Approves Humira Biosimilar; Study Examines Trifarotene for Acne Lesions
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-approves-humira-biosimilar-study-examines-trifarotene-acne-lesions/24513/In this episode of DermwireTV, the FDA approves a high-concentration Humira biosimilar; a study finds trifarotene combined with a skincare regimen was effective for acne-induced hyperpigmentation; the FDA accepts Dermavant's NDA for Vtama cream for AD; and the PA Perspective series addresses buildin